Physician profile
Bridgett Edwards
NPI 1487104501
$6,256.14
in general payments reported to CMS, 2019-2025
28 companies · $1,224 in 2025
The $1,224 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $493 · 2022: $1,582 · 2023: $1,530 · 2024: $1,427 · 2025: $1,224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,181.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,881.50 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,373.27 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $539.44 | 2021-2025 | Mounjaro, Zepbound, Emgality |
| Pfizer INC. | $508.23 | 2022-2025 | |
| Abbvie INC. | $418.48 | 2022-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $307.36 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $219.80 | 2022 | |
| Astellas Pharma US INC | $170.06 | 2023 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $133.02 | 2023-2025 | Cologuard Collection Kit |
| Nestle Healthcare Nutrition INC. | $124.50 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.48 | 2023-2024 | Xifaxan |
| Abbott Laboratories | $69.86 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $41.70 | 2021-2024 | |
| Glaxosmithkline, LLC. | $38.88 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.04 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $34.76 | 2025 | Qelbree |
| Hologic Sales and Service, LLC | $31.95 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $26.77 | 2024 | Rexulti |
| Ascend Therapeutics US, LLC | $25.71 | 2023 | |
| Amgen INC. | $25.20 | 2021-2022 | |
| Boston Scientific Corporation | $23.44 | 2023 | Watchman Access System |
| Lucid Diagnostics INC. | $20.19 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $20.18 | 2021 | |
| Ibsa Pharma INC. | $19.48 | 2021 | |
| Grt US Holding, INC. | $18.39 | 2021 | |
| Paratek Pharmaceuticals, INC. | $17.54 | 2022 | |
| Shield Therapeutics INC | $16.12 | 2025 | |
| Fidia Pharma USA INC. | $14.79 | 2023 | Hym/Hyn |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridgett Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.